DAPIPRAZOLE HYDROCHLORIDE
LOE Approachingdapiprazole hydrochloride
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dapiprazole hydrochloride is an alpha-adrenergic antagonist ophthalmic solution approved in 1990 for reversing mydriasis (pupil dilation) induced by diagnostic procedures. It is administered as eye drops to restore normal pupil size after ophthalmic examination. The drug works by blocking alpha-1 adrenergic receptors in the iris sphincter muscle.
LOE Approaching
This aging product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a contracting franchise with limited growth opportunities and likely reduced commercial team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring, typical for a mature ophthalmic product approaching LOE. Career opportunities are limited and focused on maintaining existing market share rather than growth initiatives.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.